Gynecological Cancer Drugs Market Analysis By 2018 -Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Teva Pharmaceutical Indus

Gynecological Cancer Drugs Market Overview:
The Global Gynecological Cancer Drugs Market size was valued at $9,269 million in 2016, and is expected to reach $16,107 million by 2023, growing at a CAGR of 8.1% from 2017 to 2023.Cancer refers to a specific group of disorder, which leads to abnormal cell growth within any part of the body. Gynecological cancer refers to a group of cancers that affect the reproductive organs of a female such as uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.

Request a Sample of the Report :

https://www.alliedmarketresearch.com/request-sample/3411

The growth of the global gynecological cancer drugs market is driven by factors such as increase in incidence of gynecological cancers, growth in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer. However, high cost of drug development and threat of failure & adverse effects of cancer drug therapy restrain the growth of the market. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide lucrative opportunities for the market expansion during the forecast period.

Gynecological Cancer Drugs Market Segmentation

The global gynecological cancer drugs market is segmented on the basis of therapeutic modality, indication, and region. Based on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment Review

Chemotherapy segment accounted for the largest market share in 2016, and is expected to maintain this trend throughout the forecast period. In recent years, combination chemotherapy is considered as a standard treatment mode for treatment of cancer due to its effectiveness in increase in survival & remission rates. For instance, combination therapy of gemcitabine with a platinum compound produced high response rates (as high as 71%) in patients suffering from ovarian cancer. Similarly, gemcitabine is used in combination with other compounds and cytotoxic agents for effective treatment of ovarian cancer. Popular combinations include gemcitabine with a platinum compound and paclitaxel, and gemcitabine with cisplatin or carboplatin. However, the standard approach of combination chemotherapy for treatment of epithelial ovarian cancer includes combination of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere).

For More Details , Visit :
https://www.alliedmarketresearch.com/gynecological-cancers-drugs-market

Snapshot of LAMEA Gynecological Cancer Drugs Market

Rise in focus of vendors on emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. Currently, multinational companies are focusing on investing in the GCC region as well as Latin America and Africa to expand their global reach and gain a competitive advantage. To reduce the burden of cancer, GCC member countries have established the Gulf Centre for Cancer Control and Prevention (GCCCP) that supports, services, and organizes programs for cancer control. In addition, it provides support services for the implementation of high-quality treatment care at all healthcare facilities in GCC states. GCCCP promotes cancer research in GCC member states through funding and collaboration with cancer research organizations.

Clinical Trials

Gynecological cancer drugs market has witnessed several clinical trials (5,920 trials) in the recent years, owing to increase in cancer prevalence and surge in demand for advanced healthcare facilities. The list of key players profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Key Benefits

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Analysis by therapeutic modality helps to understand the various types of treatment modalities for the treatment of gynecological cancer patients.

Comprehensive analysis of all geographical regions is provided, which helps in determining the prevailing opportunities.

Key players are profiled and their strategies are analyzed thoroughly, which helps to understand competitive outlook of the global market.

Gynecological Cancer Drugs Market Key Segments:

By Therapeutic Modality

• Chemotherapy
• Targeted Therapy
• Hormonal Therapy

By Indication

• Uterine Cancer
• Ovarian Cancer
• Vaginal & Vulvar Cancer
• Cervical Cancer

Request For Purchase Enquiry :
https://www.alliedmarketresearch.com/purchase-enquiry/3411

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.